Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis

BACKGROUND: Cancer is one of the world’s top three causes of death now. Immune checkpoint inhibitors (ICIs) show encouraging ability to treat some malignancies due to its long-term efficacy and low side effects. However, the predictive biomarker of the immunotherapy efficacy has been inconclusive. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Linghong, Wang, Zhi, Xue, Jinmin, Yang, Huaju, Zhu, Yuxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797938/
https://www.ncbi.nlm.nih.gov/pubmed/35117909
http://dx.doi.org/10.21037/tcr-20-1131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797938/
https://www.ncbi.nlm.nih.gov/pubmed/35117909
http://dx.doi.org/10.21037/tcr-20-1131

Ejemplares similares